Dworak Leiden 4

What Happened

• Dworak Leiden, Principal Accounting Officer and Vice President, Finance of TScan Therapeutics, was granted a derivative award covering 100,000 shares on January 20, 2026. The Form 4 reports the acquisition price as $0.00 (no cash paid at grant) and a reported value of $0 for the grant on the filing.

Key Details

• Transaction date: 2026-01-20; Form filed: 2026-01-22 (timely filing).
• Transaction type/code: Grant/Award (derivative); 100,000 shares reported at $0.00 per share.
• Vesting/exercise: 25% vests and becomes exercisable on the one‑year anniversary of Jan 20, 2026 (i.e., Jan 20, 2027), with the remaining shares vesting in equal monthly installments over the following 36 months (see footnote F1).
• Shares owned after transaction: Not specified in the filing.
• Notable footnote: Vesting contingent on continued service to the company on each vesting date (standard service‑based vesting).

Context

• This filing documents an option award (derivative grant) rather than an open‑market purchase or sale. The award does not provide immediate ownership of vested shares until exercised; exercise terms (other than the vesting schedule) and any exercise price beyond the $0.00 grant reporting are not detailed in the Form 4. Such grants are common as employee compensation and do not alone indicate insider intent to buy or sell company stock.